OAPI successfully commercializes Otsuka-discovered and in-licensed products in North America such as ABILIFY® (aripiprazole)1, SAMSCA® (tolvaptan)2, IV BUSULFEX® (bulsufan)3, SPRYCEL® (dasatinib)4 and BreathTek® (UBT for H. Pylori)5
OPDC clinically develops and registers innovative healthcare products on a global basis.
OMML is a basic research center investigating pharmacological compounds.
1 Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for ABILIFY.
2 Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for SAMSCA.
3 Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for IV BUSULFEX.
4 Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for SPRYCEL.
5 Please see FULL PRESCRIBING INFORMATION for BreathTek.